Advertisement

Topics

Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments

19:00 EDT 4 Sep 2017 | Pharmaceutical Technology

Janssen Pharmaceutica has entered an exclusive distribution agreement with Mundipharma Medical Company for Invokana (canagliflozin) and Vokanamet (a fixed-dose combination therapy of canagliflozin and metformin) to treat patients with type 2 diabetes

Original Article: Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments

NEXT ARTICLE

More From BioPortfolio on "Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...